Valeant Pharmaceuticals Intl (Call) (VRX) Position Lifted by Gramercy Funds Management Llc; Cameco (Ccj) (CCJ) Holder Augustine Asset Management Cut Stake by $550,287 as Share Price Declined

May 20, 2018 - By Vivian Currie

Cameco Corporation (NYSE:CCJ) Logo

Gramercy Funds Management Llc increased its stake in Valeant Pharmaceuticals Intl (Call) (VRX) by 295.26% based on its latest 2017Q4 regulatory filing with the SEC. Gramercy Funds Management Llc bought 74,700 shares as the company’s stock declined 28.77% with the market. The hedge fund held 100,000 shares of the health care company at the end of 2017Q4, valued at $2.08 million, up from 25,300 at the end of the previous reported quarter. Gramercy Funds Management Llc who had been investing in Valeant Pharmaceuticals Intl (Call) for a number of months, seems to be bullish on the $7.73 billion market cap company. The stock increased 0.50% or $0.11 during the last trading session, reaching $22.14. About 5.49 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since May 20, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Augustine Asset Management Inc decreased its stake in Cameco Corp (Ccj) (CCJ) by 59.35% based on its latest 2017Q4 regulatory filing with the SEC. Augustine Asset Management Inc sold 61,143 shares as the company’s stock declined 3.93% with the market. The institutional investor held 41,878 shares of the precious metals company at the end of 2017Q4, valued at $386,000, down from 103,021 at the end of the previous reported quarter. Augustine Asset Management Inc who had been investing in Cameco Corp (Ccj) for a number of months, seems to be less bullish one the $4.52 billion market cap company. The stock decreased 0.70% or $0.08 during the last trading session, reaching $11.36. About 1.35M shares traded. Cameco Corporation (NYSE:CCJ) has declined 17.95% since May 20, 2017 and is downtrending. It has underperformed by 29.50% the S&P500.

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 have Buy rating, 5 Sell and 15 Hold. Therefore 29% are positive. Valeant Pharmaceuticals Intl has $310 highest and $7.0 lowest target. $46.28’s average target is 109.03% above currents $22.14 stock price. Valeant Pharmaceuticals Intl had 169 analyst reports since July 21, 2015 according to SRatingsIntel. On Thursday, December 14 the stock rating was downgraded by JP Morgan to “Underweight”. The firm has “Hold” rating by BTIG Research given on Thursday, November 9. Cantor Fitzgerald maintained the shares of VRX in report on Wednesday, February 28 with “Buy” rating. On Tuesday, October 3 the stock rating was maintained by Canaccord Genuity with “Hold”. The rating was downgraded by Mizuho on Wednesday, November 23 to “Underperform”. The rating was maintained by RBC Capital Markets on Monday, October 2 with “Hold”. The stock has “Underperform” rating by Wells Fargo on Friday, February 19. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, May 2 report. The firm has “Buy” rating by Jefferies given on Wednesday, September 13. The firm has “Hold” rating given on Wednesday, October 4 by H.C. Wainwright.

Since March 8, 2018, it had 3 insider buys, and 0 sales for $876,370 activity. DE SCHUTTER RICHARD U also bought $153,400 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Thursday, March 8. The insider PAPA JOSEPH C bought 30,000 shares worth $481,500.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Benzinga.com which released: “Steve Sosnick’s Valeant Options Trade” on May 04, 2018, also Benzinga.com with their article: “Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching” published on May 19, 2018, Seekingalpha.com published: “Tracking John Paulson’s Paulson & Co. Portfolio – Q1 2018 Update” on May 18, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: Seekingalpha.com and their article: “Valeant: An Edge Into Earnings” published on April 24, 2018 as well as Seekingalpha.com‘s news article titled: “Valeant to refinance existing credit deal” with publication date: May 10, 2018.

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It is negative, as 51 investors sold VRX shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported. Marshall Wace Ltd Liability Partnership owns 0.13% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 142,832 shares. Gargoyle Inv Advisor Ltd holds 18,858 shares. Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 1.23M shares. Blackrock holds 100,000 shares. State Of Wisconsin Investment Board accumulated 237,356 shares. Cubist Systematic Strategies Ltd accumulated 34,094 shares or 0.04% of the stock. Tiaa Cref Mgmt Ltd Company reported 370,454 shares stake. First Manhattan has invested 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Gru One Trading LP has 931,893 shares for 0.14% of their portfolio. The France-based Tobam has invested 0.67% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Van Eck Assoc Corp has invested 0.07% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Perigon Wealth Mngmt holds 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 25 shares. Gulf Int Savings Bank (Uk) Limited has invested 0.03% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 1832 Asset Mngmt Lp has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Kazazian Asset Management Limited Liability Company accumulated 127,567 shares or 2.71% of the stock.

Analysts await Cameco Corporation (NYSE:CCJ) to report earnings on July, 26. They expect $0.05 earnings per share, up 162.50% or $0.13 from last year’s $-0.08 per share. CCJ’s profit will be $19.91M for 56.80 P/E if the $0.05 EPS becomes a reality. After $0.05 actual earnings per share reported by Cameco Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Augustine Asset Management Inc, which manages about $270.82M and $176.32M US Long portfolio, upped its stake in Apple Inc (Aapl) (NASDAQ:AAPL) by 3,217 shares to 82,630 shares, valued at $13.98M in 2017Q4, according to the filing. It also increased its holding in Taiwan Semiconductor (Tsm) (NYSE:TSM) by 12,039 shares in the quarter, for a total of 178,773 shares, and has risen its stake in Icici Bank (Ibn) (NYSE:IBN).

Among 6 analysts covering Cameco (NYSE:CCJ), 2 have Buy rating, 2 Sell and 2 Hold. Therefore 33% are positive. Cameco had 13 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, November 3. The company was maintained on Wednesday, April 19 by Credit Suisse. The firm earned “Sector Perform” rating on Thursday, April 7 by Scotia Capital. The firm earned “Neutral” rating on Thursday, January 12 by Bank of America. The stock of Cameco Corporation (NYSE:CCJ) earned “Neutral” rating by Bank of America on Thursday, July 21. On Tuesday, July 18 the stock rating was downgraded by Credit Suisse to “Underperform”. On Friday, October 20 the stock rating was maintained by RBC Capital Markets with “Buy”. The stock of Cameco Corporation (NYSE:CCJ) earned “Market Perform” rating by Cowen & Co on Thursday, August 6. RBC Capital Markets initiated the shares of CCJ in report on Thursday, June 29 with “Outperform” rating. The stock has “Sector Perform” rating by RBC Capital Markets on Thursday, February 2.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts